Description: Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Home Page: www.mirumpharma.com
950 Tower Lane
Foster City,
CA
94404
United States
Phone:
650 667 4085
Officers
| Name | Title |
|---|---|
| Mr. Christopher Peetz | CEO & Director |
| Mr. Peter Radovich M.B.A., Ph.D. | COO & President |
| Mr. Eric H. Bjerkholt M.B.A. | Chief Financial Officer |
| Dr. Pamela Vig Ph.D. | Chief Scientific Officer |
| Andrew McKibben | Vice President of Investor Relations and Finance |
| Mr. Paul K. Ross | Chief Compliance Officer |
| Ms. Erin Campany | Senior Vice President of Human Resources |
| Ms. Lara Longpre MBA, MSC | Chief Development Officer |
| Ms. Vinita P. Kumar | Senior vice President of Quality |
| Dr. Jean-Luc Girardet Ph.D. | Senior Vice President of Technical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 64.5161 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.1982 |
| Price-to-Sales TTM: | 6.6039 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 311 |